VYNE Therapeutics Inc. VYNE

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
37/100
Developing

Ranked against 712 peers in Biotechnology

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral … Full VYNE analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.75), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.85), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 35.6th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 22.5th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
34
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where VYNE ranks in Biotechnology

VYNE Therapeutics Inc. ranks #411 of 713 scored companies in Biotechnology by moat score — the top 58%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
407 Boundless Bio, Inc. BOLD 37/100 Developing
408 CAMP4 THERAPEUTICS CORPORATION CAMP 37/100 Developing
409 enGene Holdings Inc. Warrants ENGNW 37/100 Developing
410 enGene Holdings Inc. ENGN 37/100 Developing
411 VYNE Therapeutics Inc. VYNE 37/100 Developing
412 Coeptis Therapeutics Holdings, COEP 37/100 Developing
413 Adagene Inc. ADAG 37/100 Developing
414 Alpha Tau Medical Ltd. Warrant DRTSW 37/100 Developing
415 Alpha Tau Medical Ltd. DRTS 37/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How VYNE scores on the Corporate Default defenses

Pricing Power

Score 34 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 20 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 41 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 30 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 58 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 46 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding VYNE's moat

What is VYNE Therapeutics Inc.'s moat score?

VYNE Therapeutics Inc. (VYNE) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #411 of 713 scored companies in Biotechnology, the top 58%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (58/100) and its weakest is Cost Advantage (20/100).

How does VYNE Therapeutics Inc. compare with other Biotechnology companies?

VYNE Therapeutics Inc. ranks #411 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are enGene Holdings Inc. (ENGN) at 37 just above it and Coeptis Therapeutics Holdings, (COEP) at 37 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is VYNE Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for VYNE Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and VYNE scores: Pricing Power (34), Cost Advantage (20), Customer Stickiness (41), Capital Efficiency (30), Resilience (58), Scale & Market Position (46). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000